HealthQuill HFpEF
Denmark’s Novo Nordisk got the backing of the European Medicines Agency for its Wegovy drug to reduce heart failure in obese people.
Drugs Health Pharma

Novo’s Wegovy gets EMA nod to treat heart failure in obese people

Denmark’s Novo Nordisk got the backing of the European Medicines Agency for its Wegovy drug to reduce heart failure in obese people.

Read More
Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%, according to a statement from the Indianapolis-headquartered firm.
Drugs Health Pharma

Eli Lilly’s trial weight-loss drug reduces heart failure risk by 38%

Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%,.

Read More
X